Study of Vicor Technologies’ PD2i® Nonlinear Algorithm as Measure of Diabetic Autonomic Neuropathy Published in Clinical Neurophysiology

Share Article

“Nonlinear PD2i® heart rate complexity algorithm detects autonomic neuropathy in patients with type 1 diabetes mellitus,” authored by James Skinner, PhD, Vicor’s Vice President and Director of Research, in collaboration with Daniel Weiss, MD, Vicor’s Chief Medical Officer, and Jerry Anchin, PhD, Vicor’s Vice President and Director of Product Development, is included in the July 2011 (Volume 122 Number 7) edition of Clinical Neurophysiology.

David H. Fater, CEO of Vicor Technologies, Inc. (OTCBB: VCRT), today announced that a manuscript detailing a study of the ability of its PD2i Analyzer™ to detect the presence of autonomic neuropathy in individuals with type 1 diabetes mellitus is included in the July 2011 (Volume 122 Number 7) edition of Clinical Neurophysiology. Vicor Technologies is a biotechnology company focused on the commercialization of its PD2i Analyzer™, an innovative, non-invasive diagnostic employing its patented, proprietary PD2i® nonlinear algorithm. Physician use of the PD2i Analyzer™ is supported by an expanding body of literature documenting the PD2i® nonlinear algorithm as a metric for risk stratifying specific target populations for future pathological events, including diabetics for the presence of diabetic autonomic neuropathy (DAN), cardiovascular disease patients for death resulting from arrhythmia or congestive heart failure, and trauma victims for imminent death absent immediate lifesaving intervention.

The manuscript, titled “Nonlinear PD2i® heart rate complexity algorithm detects autonomic neuropathy in patients with type 1 diabetes mellitus,” is authored by James Skinner, PhD, Vicor’s Vice President and Director of Research, in collaboration with Daniel Weiss, MD, Vicor’s Chief Medical Officer, and Jerry Anchin, PhD, Vicor’s Vice President and Director of Product Development. It details a study to test the ability of Vicor’s PD2i Analyzer™, which measures heart rate variability with a PD2i® nonlinear algorithm score, to detect early subclinical autonomic dysfunction in young (12.9-31.5 years)asymptomatic individuals with type 1 diabetes mellitus (DM). The study demonstrates the ability of the PD2i Analyzer™ to detect autonomic nervous system dysfunction very early in asymptomatic type 1 DM patients similar to the best discriminative power of previously published complexity measures. With a P value of 0.0006, the study results are highly statistically significant.

“We’re delighted to learn that Dr. Skinner’s manuscript, co-authored by our scientific and medical team members, has been included in the July 2011 edition of Clinical Neurophysiology. The clinical study on which this manuscript is based once again demonstrated the value of our PD2i Analyzer™ as a diagnostic that provides physicians with the ability to identify those at risk of future pathological events – in this case, diabetic autonomic neuropathy – that might otherwise remain unidentified and untreated, using traditional diagnostics. Most importantly, the PD2i Analyzer™ was able to identify those patients with early subclinical autonomic dysfunction with the results of a resting ECG. Absent the PD2i Analyzer™, the standard of care for diagnosing these patients with a measure of heart rate variability depends on ECGs taken during controlled exercise and paced respiration. Given its accuracy, ease of use, and minimal data requirements, the PD2i Analyzer™ appears destined to become a valuable clinical tool for the early detection of autonomic neuropathy in type 1 DM patients,” stated Mr. Fater.

Clinical Neurophysiology is the official journal of the International Federation of Clinical Neurophysiology. It is dedicated to fostering research and disseminating information on all aspects of clinical neurophysiology, both normal and abnormal. The journal aims at publishing scholarly reports on human physiology and pathophysiology of both the central and the peripheral nervous system.

About VicorTechnologies, Inc.
Vicor Technologies’ PD2i Analyzer™ employs its patented, proprietary point correlation dimension algorithm (PD2i®), a deterministic, nonlinear measure of electrophysiological potentials that predicts future pathological events with a high degree of accuracy in target populations. Vicor anticipates use of its PD2i Analyzer™ to enable early detection and risk stratification for a variety of other disorders and diseases. Additional information is available at http://www.vicortech.com.

Disclaimer
The appearance of name-brand institutions, such as the International Federation of Clinical Neurophysiology, in this media release does not constitute endorsement by institutions of the information, products or services contained therein.

Caution Regarding Forward-Looking Statements
Forward-looking statements in this press release are based on current plans and expectations that are subject to uncertainties and risks, which could cause our future results to differ materially. The following factors, among others, could cause our actual results to differ: our ability to successfully complete the normal range study for PD2i® values; our ability to generate revenues from the sale of the PD2i Analyzer™; our ability to obtain the necessary regulatory approvals to market the PD2i Analyzer™; our ability to develop additional applications for the PD2i Analyzer™; the ability of additional sales representatives to create revenue; our ability to continue to receive financing sufficient to continue operations and complete critical clinical trials; our ability to continue as a going concern; our ability to successfully develop products based on our technologies; our ability to obtain and maintain adequate levels of third-party reimbursement for our products; the impact of competitive products and pricing; our ability to receive regulatory approval for our products; the ability of third-party contract research organizations to perform preclinical testing and clinical trials for our technologies; the ability of third-party manufacturers to manufacture our products; our ability to retain the services of our key personnel; our ability to market and sell our products successfully; our ability to protect our intellectual property; product liability; changes in federal income tax laws and regulations; general market conditions in the medical device and pharmaceutical industries; and other matters that are described in Vicor's Annual Report on Form 10-K for the fiscal year ended December 31, 2010 and subsequent filings with the Securities and Exchange Commission. Forward-looking statements in this press release speak only as of the date of the press release, and we assume no obligation to update forward-looking statements or the reasons why actual results could differ.

Release 11-16
# # #

Share article on social media or email:

View article via:

Pdf Print

Contact Author

David H. Fater

Robin Schoen
Robin Schoen Public Relations
215.504.2122
Email >
Visit website